Sleuthing molecular targets for neurological diseases at the neuromuscular junction

Nature Reviews Neuroscience

Volumn 4, Issue 5, 2003, Pages 339-352

  Engel, Andrew G ^a   Ohno, Kinji ^a   Sine, Steven M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINE ACETYLTRANSFERASE; CHOLINERGIC RECEPTOR; MUSCLE PROTEIN; PERIPHERAL MEMBRANE PROTEIN 43K;

ANIMAL; CHEMISTRY; CONGENITAL MYASTHENIC SYNDROME; ELECTROPHYSIOLOGY; GENETICS; HUMAN; METABOLISM; MUTATION; NEUROMUSCULAR SYNAPSE; PHYSIOLOGY; PROTEIN CONFORMATION; REVIEW; SYNAPTIC TRANSMISSION; CLINICAL PATHWAY; CORRELATION ANALYSIS; ENDPLATE POTENTIAL; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; MYASTHENIA; NEUROLOGIC DISEASE; NEUROMUSCULAR TRANSMISSION; PATHOGENESIS; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN STRUCTURE; SYMPTOMATOLOGY; SYNAPTIC POTENTIAL;

ACETYLCHOLINESTERASE; ANIMALS; CHOLINE O-ACETYLTRANSFERASE; ELECTROPHYSIOLOGY; HUMANS; MUSCLE PROTEINS; MUTATION; MYASTHENIC SYNDROMES, CONGENITAL; NEUROMUSCULAR JUNCTION; PROTEIN CONFORMATION; RECEPTORS, CHOLINERGIC; SYNAPTIC TRANSMISSION;

EID: 0037530441     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn1101     Document Type: Article

References (126)

1. Croxen, R., Vincent, A., Newsom-Davis, J. & Beeson, D. Myasthenia gravis in a woman with congenital AChR deficiency due to e-subunit mutation. Neurology 58, 1563-1565 (2002).
2. Salpeter, M. M. in The Vertebrate Neuromuscular Junction (ed. Salpeter, M. M.) 1-54 (Alan Liss, New York, 1987).
3. Flucher, B. E. & Daniels, M. P. Distribution of Na+ channels and ankyrin in neuromuscular junctions is complementary to that of acetylcholine receptors and the 43 kd protein. Neuron 3, 163-175 (1989).
4. Ruff, R. L. Sodium channel slow inactivation and the distribution of sodium channels on skeletal muscle fibres enable the performance properties of different skeletal muscle fibre types. Acta Physiol. Scand. 156, 159-168 (1996).
5. Martin, A. R. Amplification of neuromuscular transmission by postjunctional folds. Proc. R. Soc. Lond. B258, 321-326 (1994).
6. Wood, S. J. & Slater, C. P. Safety factor at the neuromuscular junction. Prog. Neurobiol. 64, 393-429 (2001).
7. Engel, A. G., Ohno, K. & Sine, S. M. in Myasthenia Gravis and Myasthenic Disorders (ed. Engel, A. G.) 251-297 (Oxford Univ. Press, New York, 1999).
8. Katz, B. Nerve, Muscle, and Synapse (McGraw-Hill, New York, 1966).
9. Engel, A. G. The investigation of congenital myasthenic syndromes. Ann. NY Acad. Sci. 681, 425-434 (1993).
10. Greer, M. & Schotland, M. Myasthenia gravis in the newborn. Pediatrics 26, 101-108 (1960).
11. Byring, R. F. et al. Congenital myasthenic syndrome associated with episodic apnea and sudden infant death. Neuromuscul. Disord. 12, 548-553 (2002).
12. Mora, M., Lambert, E. H. & Engel, A. G. Synaptic vesicle abnormality in familial infantile myasthenia. Neurology 37, 206-214 (1987).
13. Okuda, T. et al. Identification and characterization of the high-affinity choline transporter. Nature Neurosci. 3, 120-125 (2000).
14. Apparsundaram, S., Ferguson, S. M., George, A. L. Jr & Blakely, R. D. Molecular cloning of a human, hemicholinium-3-sensitive choline transporter. Biochem. Biophys. Res. Commun. 276, 862-867 (2000).
15. Oda, Y., Nakanishi, I. & Deguchi, T. A complementary DNA for human choline acetyltransferase induces two forms of enzyme with different molecular weights in cultured cells. Brain Res. Mol. Brain Res. 16, 287-294 (1992).
16. Erickson, J. D. et al. Functional identification of a vesicular acetylcholine transporter and its expression from a 'cholinergic' gene locus. J. Biol. Chem. 269, 21929-21932 (1994).
17. Reimer, R. J., Fon, A. E. & Edwards, R. H. Vesicular neurotransmitter transport and the presynaptic regulation of quantal size. Curr. Opin. Neurobiol. 8, 405-412 (1998).
18. Ohno, K. et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc. Natl Acad. Sci. USA 98, 2017-2022 (2001).
19. Schmidt, C. et al. Congenital myasthenic syndrome due to a novel missense mutation in the gene encoding choline acetyltransferase. Neuromuscul. Disord. 13, 245-251 (2003).
20. Maselli, R. A. et al. Choline acetyltransferase mutations in myasthenic syndrome due to deficient acetycholine resynthesis. Muscle Nerve 27, 180-187 (2003).
21. Eiden, L. E. The cholinergic gene locus. J. Neurochem. 70, 2227-2240 (1998).
22. Massoulie, J., Pezzementi, L., Bon, S., Krqd, E. & Valette, F.-M. Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 41, 31-91 (1993).
23. Massoulie, J. et al. The polymorphism of acetylcholinesterase: post-translational processing, quaternary associations and localization. Chem. Biol. interact. 119-120, 29-42 (1999).
24. Bon, S., Coussen, F. & Massoulie, J. Quaternary associations of acetylcholinesterase. II. The polyproline attachment domain of the collagen tail. J. Biol. Chem. 272, 3016-3021 (1997).
25. Krejci, E. et al. The mammalian gene of acetylcholinesterase-associated collagen. J. Biol. Chem. 272, 22840-22847 (1997).
26. Krejci, E. et al. Primary structure of a collagenic tail peptide of Torpedo acetylcholinesterase: co-expression with catalytic subunit induces the production of collagen-tailed forms in transfected cells. EMBO J. 10, 1285-1293 (1991).
27. Ohno, K., Brengman, J. M., Tsujino, A. & Engel, A. G. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc. Natl Acad. Sci. USA 95, 9654-9659 (1998).
28. Prockop, D. J. & Kivirikko, K. I. Collagens: molecular biology, diseases, and potentials for therapy. Annu. Rev. Biochem. 64, 403-434 (1995).
29. Deprez, P. N. & Inestrosa, N. C. Two heparin-binding domains are present on the collagenic tail of asymmetric acetylcholinesterase. J. Biol. Chem. 270, 11043-11046 (1995).
30. Ohno, K., Engel, A. G., Brengman, J. M., et al. The spectrum of mutations causing endplate acetylcholinesterase deficiency. Ann. Neurol. 47, 162-170 (2000).
31. Kimbell, L. M., Ohno, K., Rotundo, R. L. & Engel, A. G. Transplanting mutant human collagenic tailed acetylcholinesterase onto the frog neuromuscular junction: evidence for an attachment defect in a congenital myasthenic syndrome. Mol. Biol. Cell 12, Suppl. 161a (2001).
32. Arikawa-Hirasawa, E., Rossi, S. G., Rotundo, R. L. & Yamada, Y. Absence of acetylcholinesterase at the neuromuscular junctions of perlecan-null mice. Nature Neurosci. 5, 119-123 (2002).
33. Legay, C. et al. Collagen-tailed forms of acetylcholinesterase are anchored to the basal lamina by a dual mechanism involving perlecan and MuSK. Mol. Biol. Cell Abstr. 13, 394a-395a (2002).
34. Engel, A. G. et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann. Neurol. 11, 553-569 (1982).
35. Katz, B. & Miledi, R. The binding of acetylcholine to to receptors and its removal from the synaptic cleft. J. Physiol. (Lond.) 231, 549-574 (1973).
36. Hutchinson, D. O. et al. Congenital endplate acetylcholinesterase deficiency. Brain 116, 633-653 (1993).
37. Katz, B. & Thesleff, S. A study of the 'desensitization' produced by acetylcholine at the motor end-plate. J. Physiol. (Lond.) 138, 63-80 (1957).
38. Maselli, R. A. & Soliven, B. C. Analysis of the organophosphate-induced electromyographic response to repetitive nerve stimulation: paradoxical response to edrophonium and D-tubocurarine. Muscle Nerve 14, 1182-1188 (1991).
39. Salpeter, M. M., Kasprzak, H., Feng, H. & Fertuck, H. End-plates after esterase inactivation in vivo: correlation between esterase concentration, functional response and fine structure. J. Neurocytol. 8, 95-115 (1979).
40. Donger, C. et al. Mutation in the human acetylcholinesterase-associated gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency. Am. J. Hum. Genet. 63, 967-975 (1998).
41. Ohno, K., Brengman, J. M., Felice, K. J., Cornblath, D. R. & Engel, A. G. Congenital endplate acetylcholinesterase deficiency caused by a nonsense mutation and an A-to-G splice site mutation at position +3 of the collagen-like tail subunit gene (COLQ): how does G at position +3 result in aberrant splicing? Am. J. Hum. Genet. 65, 635-644 (1999).
42. Shapira, Y. A. et al. The novel COLQ mutations and variation of phenotypic expressivity due to G240X. Neurology 58, 603-609 (2002).
43. Ishigaki, K. et al. Two novel mutations in the ColQ gene causing endplate acetylcholinesterase deficiency. Neuromuscul. Disord. Abstr. 11, 666-667 (2001).
44. Brengman, J. M. et al. Neomutations in the collagenic tail subunit (ColQ) of acetylcholinesterase. Neurology 56, Suppl. 3, A60-A61 (2001).
45. Anderson, C. R. & Stevens, C. F. Voltage clamp analysis of acetylcholine produced end-plate current fluctuations at frog neuromuscular junction. J. Physiol. (Lond.) 235, 655-691 (1973).
46. Ohno, K. et al. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the e subunit. Proc. Natl Acad. Sci. USA. 92, 758-762 (1995).
47. Engel, A. G. et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum. Mol. Genet. 5, 1217-1227 (1996).
48. Sine, S. M. et al. Mutation of the acetylcholine receptor a-subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 15, 229-239 (1995).
49. Wang, H.-L. et al. Mutation in the M1 domain of the acetylcholine receptor a-subunit decreases the rate of agonist dissociation. J. Gen. Physiol. 109, 757-766 (1997).
50. Milone, M. et al. Slow-channel syndrome caused by enhanced activation, desensitization, and agonist binding affinity due to mutation in the M2 domain of the acetylcholine receptor a-subunit. J. Neurosci. 17, 5651-5665 (1997).
51. Gomez, C. M. et al. A p-subunit mutation in the acetylcholine receptor gate causes severe slow-channel syndrome. Ann. Neurol. 39, 712-723 (1996).
52. Croxen, R. et al. Mutations in different functional domains of the human muscle acetylcholine receptor a-subunit in patients with the slow-channel congenital myasthenic syndrome. Hum. Mol. Genet. 6, 767-774 (1997).
53. Ohno, K. et al. Slow-channel congenital myasthenic syndrome caused by a novel mutation in the acetylcholine receptor e-subunit. NeurologyAbstr. 50, A432 (1998).
54. Ohno, K. et al. Slow-channel mutations in the center of the M1 transmembrane domain of the acetylcholine receptor a-subunit. Neurology Abstr. 54, Suppl. 3, A183 (2000).
55. Gomez, C. M. et al. Novel S- and p-subunit acetylcholine receptor mutations in the slow-channel syndrome demonstrate phenotypic variability. Soc. Neurosci. Abstr. 24, 484 (1998).
56. Gomez, C. M. et al. Novel S-subunit mutation in slow- channel syndrome causes severe weakness by novel mechanism. Ann. Neurol. 51, 102-112 (2002).
57. Jackson, M. B. Perfection of a synaptic receptor: kinetics and energetics of the acetylcholine receptor. Proc. Natl Acad. Sci. USA. 86, 2199-2203 (1989).
58. Sine, S. M., Claudio, T. & Sigworth, F. J. Activation of Torpedo acetylcholine receptors expressed in mouse fibroblasts: single-channel current kinetics reveal distinct agonist binding affinities. J. Gen. Physiol. 96, 395-437 (1990).
59. Sieb, J. P, Milone, M. & Engel, A. G. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain. Res. 712, 179-189 (1996).
60. Fukudome, T., Ohno, K., Brengman, J. M. & Engel, A. G. Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. Neuroreport 9, 1907-1911 (1998).
61. Harper, C. M. & Engel, A. G. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann. Neurol. 43, 480-484 (1998).
62. Harper, C. M., Fukudome, T. & Engel, A. G. Treatment of slow channel congenital myasthenic syndrome with fluoxetine. Neurology (in the press).
63. Brejc, K. et al. Crystal structure of ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411, 269-276 (2001).
64. Sine, S. M. The nicotinic receptor ligand binding domain. J. Neurobiol. 53, 431-446 (2002).
65. Uchitel, O. et al. Congenital myasthenic syndromes. II. A syndrome attributed to abnormal interaction of acetylcholine with its receptor. Muscle Nerve 16, 1293-1301 (1993).
66. Jones, S. F. & Kwanbunbumpen, S. Some effects of nerve stimulation and hemicholinium on quantal transmitter release at the mammalian neuromuscular junction. J. Physiol. (Lond.) 207, 51-61 (1970).
67. Ohno, K. et al. Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor e subunit. Neuron 17, 157-170 (1996).
68. Shen, X.-M. et al. Mutation causing severe myasthenia reveals functional asymmetry of AChR signature Cys-loops in agonist binding and gating. J. Clin. invest 111, 497-505 (2003).
69. Wang, H.-L. et al. Acetylcholine receptor M3 domain: stereochemical and volume contributions to channel gating. Nature Neurosci. 2, 226-233 (1999).
70. Milone, M. et al. Mode switching kinetics produced by a naturally occurring mutation in the cytoplasmic loop of the human acetylcholine receptor e-subunit. Neuron 20, 575-588 (1998).
71. Wang, H.-L. et al. Fundamental gating mechanism of nicotinic receptor channel revealed by mutation causing a congenital myasthenic syndrome. J. Gen. Physiol. 116, 449-460 (2000).
72. Brownlow, S. et al. Acetylcholine receptor S subunit mutations underlie a fast-channel myasthenic syndrome and arthrogryposis multiplex congenita. J. Clin. invest. 108, 125-130 (2001).
73. Sine, S. M. et al. Naturally occurring mutations at the acetylcholine receptor binding site independently alter ACh binding and channel gating. J. Gen. Physiol. 120, 483-496 (2002).
74. Zhong, W., Gallivan, J. P., Zhang, Y., Li, L., Lester, H. A. & Dougherty, D. A. From ab initio quantum mechanics to molecular neurobiology: a cation-n binding site in the nicotinic receptor. Proc. Natl Acad. Sci. USA 95, 12088-12093 (1998).
75. Sine, S. M., Wang, H.-L. & Bren, N. Lysine scanning mutagenesis delineates structure of nicotinic receptor binding domain. J. Biol. Chem. 277, 29210-29223 (2002).
76. Thomsen, R. H. & Wilson, D. F. Effect of 4-aminopyridine and 3, 4-diaminopyridineon transmitter release at the neuromuscular junction. J. Pharmacol. Exp. Therap. 227, 260-265 (1983).
77. Engel, A. G., Ohno, K., Bouzat, C., Sine, S. M. & Griggs, R. G. End-plate acetylcholine receptor deficiency due to nonsense mutations in the e subunit. Ann. Neurol. 40, 810-817 (1996).
78. Ohno, K. et al. Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor e subunit gene: identification and functional characterization of six new mutations. Hum. Mol. Genet. 6, 753-766 (1997).
79. Witzemann, V. et al. Acetylcholine receptor e subunit deletion causes muscle weakness and atrophy in juvenile and adult mice. Proc. Natl Acad. Sci. USA. 93, 13286-13291 (1996).
80. Croxen, R. et al. Endplate y- and e-subunit mRNA levels in AChR deficiency syndrome due to e-subunit null mutations. Brain 124, 1362-1372 (2001).
81. Ohno, K. et al. Myasthenic syndromes in Turkish kinships due to mutations in the acetylcholine receptor. Ann. Neurol. 44, 234-241 (1998).
82. Abicht, A. et al. A common mutation (e1267delG) in congenital myasthenic patients of Gipsy ethnic origin. Neurology 53, 1564-1569 (1999).
83. Middleton, L. et al. Congenital myasthenic syndromes linked to chromosome 17p are caused by defects in acetylcholine receptor e subunit gene. Neurology 53, 1076-1082 (1999).
84. Croxen, R. et al. Novel functional e-subunit polypeptide generated by a single nucleotide deletion in acetylcholine receptor deficiency congenital myasthenic syndrome. Ann. Neurol. 46, 639-647 (1999).
85. Shen, X.-M. et al. Congenital myasthenic syndrome caused by low-expressor fast-channel AChR S subunit mutation. Neurology 59, 1881-1888 (2002).
86. Ealing, J. et al. Mutations in congenital myasthenic syndromes reveal an e subunit C-terminal cysteine, C470, crucial for maturation and surface expressions of adult AChR. Hum. Mol. Genet. 11, 3087-3096 (2002).
87. Abicht, A., Stucka, R., Schmidt, C., et al. A newly identified chromosomal microdeletion and an N-box mutation of the AChRe gene cause a congenital myasthenic syndrome. Brain 125, 1005-1013 (2002).
88. Ohno, K., Anlar, B. & Engel, A. G. Congenital myasthenic syndrome caused by a mutation in the Ets-binding site of the promoter region of the acetylcholine receptor e subunit gene. Neuromuscul. Disord. 9, 131-135 (1999).
89. Nichols, P. R. et al. Mutation of the acetylcholine receptor e-subunit promoter in congenital myasthenic syndrome. Ann. Neurol. 45, 439-443 (1999).
90. Duclert, A., Savatier, N., Schaeffer, L. & Changeux, J.-P. Identification of an element crucial for the sub-synaptic expression of the acetylcholine receptor e-subunit gene. J. Biol. Chem. 271, 17433-17438 (1996).
91. Schaeffer, L., Duclert, N., Huchet-Dymanus, M. & Changeux, J.-P. Implication of a multisubunit Ets-related transcription factor in synaptic expression of the nicotinic acetylcholine receptor. EMBO J. 17, 3078-3090 (1998).
92. Fromm, L. & Burden, S. J. Synapse-specific and neuregulin-induced transcription require an Ets site that binds GABPa/GAPBp. Genes Dev. 12, 3074-3083 (1998).
93. Quiram, P. et al. Mutation causing congenital myasthenia reveals acetylcholine receptor p/S subunit interaction essential for assembly. J. Clin. Invest. 104, 1403-1410 (1999).
94. Ohno, K. & Engel, A. G. Congenital myasthenic syndromes: gene mutations. Neuromuscul. Disord. 12, 807-811 (2002).
95. Froehner, S. C., Luetje, C. W., Scotland, P. B. & Patrick, J. The postsynaptic 43K protein clusters muscle nicotinic acetylcholine receptors in Xenopus oocytes. Neuron 5, 403-410 (1990).
96. Gautam, M. et al. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice. Nature 377, 232-236 (1995).
97. Willman, R. & Fuhrer, C. Neuromuscular synaptogenesis. Cell. Mol. Life Sci. 59, 1296-1316 (2002).
98. Marchand, S., Bignami, F., Stetzkowski-Marden, F. & Cartaud, J. The myristoylated protein rapsyn is cotargeted with the nicotinic acetylcholine receptor to the postsynaptic membrane via the exocytic pathway. J. Neurosci. 20, 521-528 (2000).
99. Marchand, S., Devillers-Thiery, A., Pons, S., Changeux, J.- P. & Cartaud, J. Rapsyn escorts the nicotinic acetylcholine receptor along the exocytic pathway via association with lipid rafts. J. Neurosci. 22, 8891-8901 (2002).
100. Maimone, M. M. & Merlie, J. P. Interaction of the 43 kd postsynaptic protein with all subunits of the muscle nicotinic acetylcholine receptor. Neuron 11, 53-66 (1993).
101. Maimone, M. M. & Enigk, R. E. The intracellular domain of the nicotinic acetylcholine receptor a subunit mediates its coclustering with rapsyn. Mol. Cell. Neurosci. 14, 340-354 (1999).
102. Cartaud, A., Coutant, S., Petrucci, T. C. & Cartaud, J. Evidence for in situ and in vitro association between p-dystroglycan and the subsynaptic 43K rapsyn protein. Consequence for acetylcholine receptor clustering at the synapse. J. Biol. Chem. 273, 11321-11326 (1998).
103. Ramarao, M. K. & Cohen, J. B. Mechanism of nicotinic acetylcholine receptor cluster formation by rapsyn. Proc. Natl Acad. Sci. USA 95, 4007-4012 (1998).
104. Ramarao, M. K., Bianchetta, M. J., Lanken, J. & Cohen, J. B. Role of rapsyn tetratrichopeptide repeat and coiled- coil domains in self-association and nicotinic acetylcholine receptor clustering. J. Biol. Chem. 276, 7475-7483 (2001).
105. Bartoli, M. & Cohen, J. B. Identification of the modular domains of rapsyn binding to nicotinic acetylcholine receptor (AChR) and to dystroglycan. Soc. Neurosci. Abstr. 27, 904.16 (2001).
106. Bartoli, M., Ramarao, M. K. & Cohen, J. B. Interactions of the rapsyn RING-H2 domain with dystroglycan. J. Biol. Chem. 276, 24911-24917 (2001).
107. Lee, Y. I., Swope, S. L. & Ferns, M. J. Rapsyn's C-terminal domain mediates MuSK-induced phosphorylation of the AChR. Mol. Biol. Cell Abstr. 13, 395a (2002).
108. Yun, K. & Wold, B. Skeletal muscle determination and differentiation: story of a core regulatory network and its content. Curr. Opin. Cell Biol. 8, 877-889 (1996).
109. Ohno, K. et al. Rapsyn mutations in humans cause endplate acetylcholine receptor deficiency and myasthenic syndrome. Am. J. Hum. Genet. 70, 875-885 (2002).
110. Ohno, K., Sadeh, M., Blatt, I., Brengman, J. M. & Engel, A. G. E-box mutations in RAPSN promoter region in eight cases with congenital myasthenic syndrome. Hum. Mol. Genet. 12, 739-748 (2003).
111. Gautam, M. et al. Defective neuromuscular synaptogenesis in agrin-deficient mutant mice. Cell85, 525-535 (1996).
112. Burgess, R. W., Nguyen, Q. T., Son, Y. J., Lichtman, J. W. & Sanes, J. R. Alternatively spliced isoforms of nerve- and muscle-derived agrin: their roles at the neuromuscular junction. Neuron 23, 33-44 (1999).
113. Glass, D. J. et al. Agrin acts via MuSK receptor complex. Cell 85, 513-523 (1996).
114. Apel, E. D., Glass, D. J., Moscosco, L. M., Yancopoulos, G. D. & Sanes, J. R. Rapsyn is required for MuSK signaling and recruits synaptic components to a MuSK-containing scaffold. Neuron 18, 623-625 (1997).
115. Smith, C. L., Mittaud, P., Prescott, E. D., Fuhrer, C. & Burden, S. J. Src, Fyn, and Yes are not required for neuromuscular synapse formation but are necessary for stabilization of agrin-induced clusters of acetylcholine receptors. J. Neurosci. 21, 3151-3160 (2001).
116. Sandrock, A. W. et al. Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. Science 276, 599-603 (1997).
117. Si, J., Luo, Z. & Mei, L. Induction of acetylcholine receptor gene expression by ARIA requires activation of mitogen- activated protein kinase. J. Biol. Chem. 271, 19752-19759 (1996).
118. Altiok, N., Altiok, K. & Changeux, J.-P Heregulin-stimulated acetylcholine receptor gene expression in muscle: requirement for MAP kinase and evidence for parallel inhibitory pathway independent electrical activity EMBO J. 16, 717-725 (1997).
119. Belluardo, N. et al. Neuromuscular junction disassembly and muscle fatigue in mice lacking neurotrophin-4. Mol. Cell. Neurosci. 18, 56-67 (2001).
120. Gonzales, M. et al. Disruption of Trkb-mediated signaling induces disassembly of potsynaptic receptor clusters at neuromuscular junctions. Neuron 24, 567-583 (1999).
121. Newey, S. A. et al. A novel mechanism for modulating synaptic gene expression: differential localization of a- dystrobrevin transcripts in skeletal muscle. Mol. Cell. Neurosci. 17, 127-140 (2001).
122. Grady, R. M., Merlie, J. P. & Sanes, J. R. Subtle neuromuscular defects in utrophin-deficient mice. J. Cell Biol. 136, 871-882 (1997).
123. Adams, M. E. et al. Absence of a-syntrophin leads to structurally aberrant neuromuscular synapses deficient in utrophin. J. Cell Biol. 150, 1385-1398 (2000).
124. Croxen, R. et al. Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. Neurology 59, 162-168 (2002).
125. Karlin, A. Emerging structure of the nicotinic acetylcholine receptors. Nature Rev. Neurosci. 3, 102-114 (2002).
126. Unwin, N., Miyazawa, A., Li, J. & Fujiyoshi, Y. Activation of the nicotinic acetylcholine receptor involves a switch in conformation of the a subunits. J. Mol. Biol. 319, 1165-1176 (2002).